In multiple sclerosis (MS) studies, the most appropriate model for the distribution of the number of relapses was shown to be the negative binomial (NB) distribution.
Objective:
To determine whether the sample-size estimation (SSE) and the analysis of annualized relapse rates (ARRs) in randomized controlled trials (RCTs) were aligned and compare the SSE between normal and NB distributions.
Methods:
Systematic review of phase 3 and 4 RCTs for which the primary endpoint was ARR in relapsing remitting MS published since 2008 in pre-selected major medical journals. A PubMed search was performed on 30 November 2020. We checked whether the SSE and ARR analyses were congruent. We also performed standardized (fixed α/β, number of arms and overdispersion) SSEs using data collected from the studies.
Results:
Twenty articles (22 studies) were selected. NB distribution (or quasi-Poisson) was used for SSE in only 7/22 studies, whereas 21/22 used it for ARR analyses. SSE relying on NB regression necessitated a smaller sample size in 21/22 of our calculations.
Conclusion:
SSE was rarely performed using the most appropriate model. However, the use of an NB model is recommended to optimize the number of included patients and to be congruent with the final analysis.
FambiatosAJokubaitisVHorakovaD, et al. Risk of secondary progressive multiple sclerosis: A longitudinal study. Mult Scler2020; 26(1): 79–90.
2.
WangYCMeyersonLTangYQ, et al. Statistical methods for the analysis of relapse data in MS clinical trials. J Neurol Sci2009; 285: 206–211.
3.
Ver HoefJMBovengPL. Quasi-Poisson vs. negative binomial regression: how should we model overdispersed count data?Ecology2007; 88(11): 2766–2772.
4.
FriedeTPohlmannHSchmidliH.Blinded sample size reestimation in event-driven clinical trials: Methods and an application in multiple sclerosis. Pharm Stat2019; 18(3): 351–365.
5.
MoissetXFouchardA-APereiraB, et al. Untreated patients with multiple sclerosis: A study of French expert centers. Eur J Neurol2021; 28(6): 2026–2036.
6.
HauserSLBar-OrAComiG, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med2017; 376: 221–234.
7.
HauserSLBar-OrACohenJA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med2020; 383: 546–557.
8.
GoldRGiovannoniGSelmajK, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): A randomised, double-blind, placebo-controlled trial. Lancet Lond Engl2013; 381: 2167–2175.
9.
ConfavreuxCO’ConnorPComiG, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol2014; 13(3): 247–256.
10.
ComiGJefferyDKapposL, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med2012; 366: 1000–1009.
11.
KapposLWiendlHSelmajK, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med2015; 373: 1418–1428.
12.
CreeBACGoldmanMDCorboyJR, et al. Efficacy and safety of 2 fingolimod doses vs glatiramer acetate for the treatment of patients with relapsing-remitting multiple sclerosis: A randomized clinical trial. JAMA Neurol2020; 78: 1–13.
13.
LublinFDCofieldSSCutterGR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol2013; 73(3): 327–340.
14.
GiovannoniGComiGCookS, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med2010; 362: 416–426.
15.
CohenJABarkhofFComiG, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med2010; 362: 402–415.
16.
HavrdovaEZivadinovRKrasenskyJ, et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler2009; 15(8): 965–976.
17.
SorensenPSMellgrenSISvenningssonA, et al. NORdic trial of oral methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting multiple sclerosis (NORMIMS study): A randomised, placebo-controlled trial. Lancet Neurol2009; 8(6): 519–529.
18.
KapposLRadueE-WO’ConnorP, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med2010; 362: 387–401.
19.
ComiGCohenJAArnoldDL, et al. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol2011; 69(1): 75–82.
20.
O’ConnorPWolinskyJSConfavreuxC, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med2011; 365: 1293–1303.
21.
SorensenPSLyckeJErälinnaJP, et al. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): A placebo-controlled randomised phase 4 trial. Lancet Neurol2011; 10(8): 691–701.
22.
FoxRJMillerDHPhillipsJT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med2012; 367: 1087–1097.
23.
KhanORieckmannPBoykoA, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol2013; 73: 705–713.
24.
CalabresiPARadueE-WGoodinD, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol2014; 13(6): 545–556.
25.
CalabresiPAKieseierBCArnoldDL, et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): A randomised, phase 3, double-blind study. Lancet Neurol2014; 13(7): 657–665.
26.
SormaniMPRovarisMComiG, et al. A composite score to predict short-term disease activity in patients with relapsing-remitting MS. Neurology2007; 69: 1230–1235.
27.
InusahSSormaniMPCofieldSS, et al. Assessing changes in relapse rates in multiple sclerosis. Mult Scler2010; 16(12): 1414–1421.
28.
SteinvorthSMRöverCSchneiderS, et al. Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: Systematic review and meta-regression. Mult Scler2013; 19(12): 1580–1586.
29.
NicholasRStraubeSSchmidliH, et al. Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: A systematic review and meta-analysis. Mult Scler2012; 18(9): 1290–1296.
30.
TramacereIDel GiovaneCSalantiG, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: A network meta-analysis. Cochrane Database Syst Rev2015; 6: CD011381.
31.
SalantiGNikolakopoulouASuttonAJ, et al. Planning a future randomized clinical trial based on a network of relevant past trials. Trials2018; 19: 365.
32.
SormaniMPSignoriASiriP, et al. Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler2013; 19(4): 466–474.
33.
BrissetJ-CKremerSHannounS, et al. New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions. J Neuroradiol2020; 47(4): 250–258.
34.
TurCMocciaMBarkhofF, et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol2018; 14(2): 75–93.
35.
OliveiraMLLucchettaRCBonettiA, et al. Efficacy outcomes reported in trials of multiple sclerosis: A systematic scoping review. Mult Scler Relat Disord2020; 45: 102435.
36.
BurnettTMozgunovPPallmannP, et al. Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs. BMC Med2020; 18: 352.
37.
FriedeTSchmidliH. Blinded sample size reestimation with negative binomial counts in superiority and non-inferiority trials. Methods Inf Med2010; 49(6): 618–624.
38.
SormaniMPBruzziPMillerDH, et al. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. J Neurol Sci1999; 163: 74–80.
